Scleroderma News

SAN DIEGO — Shortness of breath, male sex, age and elevated inflammatory markers are all more predictive of new interstitial lung disease in systemic sclerosis than disease duration, according to data presented at ACR Convergence 2023.

The FDA has granted 510(k) clearance to Werfen for its Aptiva Connective Tissue Disease Essential reagent to assist in the diagnosis of patients with autoimmune diseases, according to a manufacturer press release.

The FDA has approved an investigational new drug application for Kyverna Therapeutics’ KYV-101, an anti-CD19 chimeric antigen receptor T-cell therapy for diffuse cutaneous systemic sclerosis, according to a company press release.

The prevalence of neuropsychiatric symptoms in patients with systemic autoimmune rheumatic diseases is significantly “higher and more wide-ranging” than previously recognized, according to data published in Rheumatology.

The FDA has granted an investigational new drug application for CABA-201, a 4-1BB-containing fully human CD19-CAR T-cell therapy, to be studied in patients with systemic sclerosis, according to a press release from its manufacturer.

Physical exercise “should be considered” in patients with either systemic lupus erythematosus or systemic sclerosis, according to new EULAR recommendations on non-pharmacologic management published in the Annals of the Rheumatic Diseases.

Patients with inflammatory rheumatic diseases are as likely as the general population to contract COVID-19, but are at a higher risk for severe outcomes, including hospitalization and death, according to data.

Patients with systemic sclerosis-associated interstitial lung disease who receive nintedanib demonstrate a higher risk for malnutrition, compared with placebo, according to data published in Arthritis Care & Research.

SAN DIEGO — Rheumatologists should stratify patients with systemic sclerosis-associated interstitial lung disease into phenotypes in order to closely monitor those with progressing disease, according to a speaker here.

Nintedanib slows the deterioration of lung functionality in patients with limited cutaneous systemic sclerosis and interstitial lung disease, according to data published in Rheumatology.